



PATENT Attorney Docket 056291-5374

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: <b>D. R. Carcanague</b> et al.	)
Application No. 10/536,686	) Art Unit: <b>1625</b>
Filed: May 27, 2005	) Examiner: Morris, Patricia L.
For: Oxazolidinone and/or Isoxazoline Derivatives as Antibacterial Agents	)
ð	) Date: June 20, 2007

U.S. Patent and Trademark Office Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314

## SUBMISSION OF REVOCATION OF POWER OF ATTORNEY AND GRANT OF NEW POWER OF ATTORNEY

Enclosed is a Revocation of Power of Attorney With New Power of Attorney and Change of Correspondence Address. Please associate this application with Customer Number 09629.

Dated: June 20, 2007 Morgan, Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 202-739-3000 Respectfully submitted,
Morgan, Lewis & Bockius LLP

Gregory T. Lowen, Ph.E Registration No. 46,882



PTO/SB/82 (01-06)
Approved for use through 12/31/2008. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to res

## **REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY** AND **CHANGE OF CORRESPONDENCE ADDRESS**

conditor a confection of the inflation unit	ess it displays a valid OMB cuttion fulfiber.				
Application Number	10/536,686				
Filing Date	05-27-2005				
First Named Inventor	Daniel Carcanague				
Art Unit	1625				
Examiner Name	Morris, Patricia L				
Attorney Docket Number	100861-1P US				

1 hereby re	voke all pn	evious powers of	attornev given in th	e above-ide	ntified appli	cation.		
A Pow	ver of Attorn	ney is submitted her	rewith.					
OR  ✓ I hereby appoint the practitioners associated with the Customer Number:				ber:	9629			
[ TI	_	associated with	address for the above	-identified a	pplication to:			
OR		mbei.						
Firm of	<i>r</i> ual Name							
Address								
City			Star	е		Zip		
Country								
Telephone				Email				
I am the: Appl	icant/Inven	tor.						
		37 CFR 3.73(b) is	erest. See 37 CFR 3. enclosed. (Form PT	D/SB/96)				
	· · · · · · ·	SIGNATUR	RE of Applicant or A	ssignee of	Record			
Signature	1=	5) or	<u> </u>					
Name	TRAC	EY BRYA			<del>                                     </del>		<del>,                                     </del>	
Date	6/1/	(00)		Telephone	+441			1322
NOTE: Signature signature is requi		tors or assignees of record	of the entire interest or their r	epresentative(s) a	re required. Subri	iit multiple for	rms if more than	one
*Total o	of	forms are submitted.						

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SE/96 (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATE	EMENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner: <u>Daniel Robert Carcanague</u>	e, Michael Barry Gravestock, Sheila Irene Hauck, Thomas Peter Weber, Neil James मिन्हा (
Application No./Patent No.: 10/536,686	Filed/Issue Date: 05-27-2005
Entitled: OXAZOLIDINONE AND/OR ISOXAZOLINE	DERIVATIVES AS ANTIBACTERIAL AGENTS
AstraZeneca AB	
(Name of Assignee)	(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is:  1.  the assignee of the entire right, title, and interest in the state of the entire right.	terest; or
<ol> <li>an assignee of less than the entire right, titl (The extent (by percentage) of its ownershi</li> </ol>	
in the patent application/patent identified above b	y virtue of either:
	oatent application/patent identified above. The assignment was recorded Office at Reel _019350, Frame _0595, or for which a copy
OR  B. A chain of title from the inventor(s), of the page	atent application/patent identified above, to the current assignee as follows:
1. From:	То:
The document was recorded in the U	United States Patent and Trademark Office at, or for which a copy thereof is attached.
2. From:	To:
The document was recorded in the U	United States Patent and Trademark Office at or for which a copy thereof is attached.
3. From:	To:
The document was recorded in the L	Inited States Patent and Trademark Office at, or for which a copy thereof is attached.
Additional documents in the chain of title	are listed on a supplemental sheet.
As required by 37 CFR 3.73(b)(1)(i), the doct assignee was, or concurrently is being, submitted	umentary evidence of the chain of title from the original owner to the for recordation pursuant to 37 CFR 3.11.
	he original assignment document(s)) must be submitted to Assignment 3, to record the assignment in the records of the USPTO. <u>See</u> MPEP
The undersigned (whose title is supplied below) is	authorized to act on behalf of the assignee.
_ ,	+ 44(6) 1625 513228
Printed or Typed Na	arme Telephone Number
	ONCOLOGY AND INFECTION
Titlo	- 1 1 CC

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to flie (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.